{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:35:53Z","timestamp":1783654553072,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejca.2024.115078","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T22:10:31Z","timestamp":1729375831000},"page":"115078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study"],"prefix":"10.1016","volume":"213","author":[{"given":"Arun A.","family":"Azad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Joung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.C.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Dunshee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Carles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre P.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"DeAnnuntis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.115078_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol Pr"},{"key":"10.1016\/j.ejca.2024.115078_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115078_bib3","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1634\/theoncologist.2019-0493","article-title":"Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the Phase III EMBRACA trial","volume":"25","author":"Hurvitz","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.115078_bib4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115078_bib5","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-18-1891","article-title":"A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1\/2 mutations (ABRAZO)","volume":"25","author":"Turner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.115078_bib6","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1093\/oncolo\/oyac172","article-title":"Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses","volume":"27","author":"Mehra","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.115078_bib7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115078_bib8","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2147\/DDDT.S147726","article-title":"Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials","volume":"11","author":"Zhou","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ejca.2024.115078_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2024.115078_bib10","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115078_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.115078_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.115078_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2217\/fon-2021-0811","article-title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design","volume":"18","author":"Agarwal","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2024.115078_bib14","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) v4.03, \u3008https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010\u201306-14_QuickReference_8.5\u00d711.pdf\u3009; Updated June 2010 [accessed 1 April 2023]."},{"key":"10.1016\/j.ejca.2024.115078_bib15","unstructured":"U.S. Food and Drug Administration. TALZENNA\u00ae (talazoparib) prescribing information, \u3008https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11046\u3009; Revised February 2024 [accessed 23 May 2024]."},{"key":"10.1016\/j.ejca.2024.115078_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2024.115078_bib17","article-title":"Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy","author":"Shore","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ejca.2024.115078_bib18","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/jcph.1626","article-title":"Exposure-safety analyses of talazoparib in patients with advanced breast cancer and germline BRCA1\/2 mutations in the EMBRACA and ABRAZO trials","volume":"60","author":"Elmeliegy","year":"2020","journal-title":"J Clin Pharm"},{"key":"10.1016\/j.ejca.2024.115078_bib19","unstructured":"U.S. Food and Drug Administration. RUBRACA\u00ae (rucaparib) prescribing information, \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209115s004lbl.pdf\u3009; Revised May 2020 [accessed 6 June 2024]."},{"key":"10.1016\/j.ejca.2024.115078_bib20","unstructured":"U.S. Food and Drug Administration. LYNPARZA\u00ae (olaparib) prescribing information, \u3008https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9\u2013106b-4550-b5d0\u201312b045f8b184\/00997c3f-5912\u2013486f-a7db-930b4639cd51\/00997c3f-5912\u2013486f-a7db-930b4639cd51_viewable_rendition__v.pdf\u3009; Revised November 2023 [accessed 6 June 2024]."},{"key":"10.1016\/j.ejca.2024.115078_bib21","unstructured":"U.S. Food and Drug Administration. AKEEGA\u2122 (niraparib and abiraterone acetate) tablets, for oral use, \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216793s000lbl.pdf\u3009; Published August 2023 [accessed 6 June 2024]."},{"key":"10.1016\/j.ejca.2024.115078_bib22","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2025.116106","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924012097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924012097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T03:51:53Z","timestamp":1764820313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924012097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":22,"alternative-id":["S0959804924012097"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115078","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115078"}}